Eisai’s Leqembi Launch Bodes Well For Biogen In A Pivotal Year
Executive Summary
Eisai said the US launch of Alzheimer’s therapy Leqembi following accelerated approval is going well, which is welcome news for partner Biogen as it brings on a new CEO and recovers from a failed Aduhelm launch.
You may also be interested in...
ICER’s Leqembi Assessment Inches Higher, Still Sees Eisai Price As Too High
The drug pricing watchdog said in its revised report that Alzheimer’s therapy Leqembi (lecanemab) meets cost-effectiveness thresholds at $8,900-$21,500, below Eisai/Biogen’s $26,500 list price.
UPDATED: US FDA Has People Working At CMS To Help Implement Inflation Reduction Act
The FDA was mum on the expertise that it appears to be lending the payer, but Commissioner Robert Califf reiterated that communication between the agency and CMS is increasing.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.